Steven G Waguespack

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7314522/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1239-1246.	3.6	9
2	Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. European Journal of Endocrinology, 2022, 186, 631-643.	3.7	55
3	Management of adrenocorticotropic hormone-secreting neuroendocrine tumors and the role of bilateral adrenalectomy in ectopic Cushing syndrome. Surgery, 2022, 172, 559-566.	1.9	5
4	Larotrectinib Before Initial Radioactive Iodine Therapy in Pediatric TRK Fusion–Positive Papillary Thyroid Carcinoma: Time to Reconsider the Treatment Paradigm for Distantly Metastatic Disease?. JCO Precision Oncology, 2022, 6, e2100467.	3.0	8
5	Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head and Neck, 2021, 43, E7-E12.	2.0	42
6	Pheochromocytoma/Paraganglioma, Medullary Thyroid Carcinoma, and Hereditary Endocrine Neoplasia Syndromes. , 2021, , 491-527.		1
7	Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2198-2207.	3.6	37
8	lt's not a mystery, it's in the history: Multidisciplinary management of multiple endocrine neoplasia type 1. Ca-A Cancer Journal for Clinicians, 2021, 71, 369-380.	329.8	4
9	Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns. Endocrine-Related Cancer, 2021, 28, 419-431.	3.1	29
10	Decision Making When Cancer Becomes Chronic: Needs Assessment for a Web-Based Medullary Thyroid Carcinoma Patient Decision Aid. JMIR Formative Research, 2021, 5, e27484.	1.4	3
11	Multiple endocrine neoplasia syndromes and somatotroph adenomas. , 2021, , 173-195.		0
12	Distant Metastases From Childhood Differentiated Thyroid Carcinoma: Clinical Course and Mutational Landscape. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1683-1697.	3.6	42
13	An Adolescent with Papillary Thyroid Carcinoma and Locally Metastatic Disease but No Distant Metastases. , 2021, , 93-102.		1
14	A Child with Papillary Thyroid Cancer and Metastatic Pulmonary Disease: Role of Radioactive Iodine Therapy. , 2021, , 209-219.		1
15	Prevalence and Risk Factors for Multifocality in Pediatric Thyroid Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 1100.	2.2	12
16	Imaging features of adrenal gland masses in the pediatric population. Abdominal Radiology, 2020, 45, 964-981.	2.1	20
17	Risks of Hypoparathyroidism After Total Thyroidectomy in Children: A 21‥ear Experience in a Highâ€Volume Cancer Center. World Journal of Surgery, 2020, 44, 442-451.	1.6	27
18	Imaging of Adrenal-Related Endocrine Disorders. Radiologic Clinics of North America, 2020, 58, 1099-1113.	1.8	5

#	Article	IF	CITATIONS
19	The Afirma Xpression Atlas for thyroid nodules and thyroid cancer metastases: Insights to inform clinical decisionâ€making from a fineâ€needle aspiration sample. Cancer Cytopathology, 2020, 128, 452-459.	2.4	36
20	Genetic profiling as a clinical tool in advanced parathyroid carcinoma. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1977-1986.	2.5	30
21	Analytical and Clinical Validation of Expressed Variants and Fusions From the Whole Transcriptome of Thyroid FNA Samples. Frontiers in Endocrinology, 2019, 10, 612.	3.5	42
22	The Clinical Impact of [⁶⁸ Ga]â€DOTATATE PET/CT for the Diagnosis and Management of Ectopic Adrenocorticotropic Hormone – Secreting Tumours. Clinical Endocrinology, 2019, 91, 288-294.	2.4	31
23	Genetic characterization of medullary thyroid cancer in childhood survivors of the Chernobyl accident. Surgery, 2019, 165, 58-63.	1.9	5
24	Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes and Endocrinology,the, 2019, 7, 213-220.	11.4	86
25	Thyroid Sequelae of Pediatric Cancer Therapy. Hormone Research in Paediatrics, 2019, 91, 104-117.	1.8	18
26	Treatment and long-term outcomes in pituitary carcinoma: a cohort study. European Journal of Endocrinology, 2019, 181, 397-407.	3.7	25
27	Thyroid Neoplasia. , 2018, , 439-476.		1
28	Recontacting Patients with Updated Genetic Testing Recommendations for Medullary Thyroid Carcinoma and Pheochromocytoma or Paraganglioma. Annals of Surgical Oncology, 2018, 25, 1395-1402.	1.5	11
29	Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma. Annals of Surgery, 2018, 268, 172-178.	4.2	75
30	Electrolyte Disturbances in Critically III Cancer Patients: An Endocrine Perspective. Journal of Intensive Care Medicine, 2018, 33, 147-158.	2.8	13
31	A comprehensive review on MEN2B. Endocrine-Related Cancer, 2018, 25, T29-T39.	3.1	58
32	Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer. Head and Neck, 2018, 40, 79-85.	2.0	25
33	Endocrine Sequelae of Central Nervous System Irradiation. , 2018, , 537-551.		0
34	Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. Clinical Cancer Research, 2018, 24, 753-765.	7.0	26
35	Survey on Paediatric Differentiated Thyroid Cancer Care in Europe. Hormone Research in Paediatrics, 2018, 89, 58-62.	1.8	8
36	Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3698-3705.	3.6	91

#	Article	IF	CITATIONS
37	Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. Lancet Oncology, The, 2018, 19, 1351-1359.	10.7	63
38	Effect of Tumor Size and Minimal Extrathyroidal Extension in Patients with Differentiated Thyroid Cancer. Thyroid, 2018, 28, 982-990.	4.5	62
39	Extrathyroidal Extension: Does Strap Muscle Invasion Alone Influence Recurrence and Survival in Patients with Differentiated Thyroid Cancer?. Annals of Surgical Oncology, 2018, 25, 3380-3388.	1.5	46
40	Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. Thyroid, 2018, 28, 1243-1251.	4.5	160
41	Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions. Thyroid, 2018, 28, 1301-1310.	4.5	96
42	Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions. Oncologist, 2017, 22, 255-263.	3.7	60
43	Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2807-2813.	3.6	53
44	Cushing Syndrome: Diagnostic Workup and Imaging Features, With Clinical and Pathologic Correlation. American Journal of Roentgenology, 2017, 209, 19-32.	2.2	47
45	Visual Vignette. Endocrine Practice, 2017, 23, 1160.	2.1	0
46	Long-Term Outcomes of Lateral Neck Dissection in Patients with Recurrent or Persistent Well-Differentiated Thyroid Cancer. Thyroid, 2017, 27, 1291-1299.	4.5	17
47	Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3591-3599.	3.6	63
48	Significant response of pituitary carcinoma to carboplatin, leucovorin and fluorouracil chemotherapy: a pediatric case report and review of the literature. Journal of Neuro-Oncology, 2017, 135, 213-215.	2.9	12
49	Operative intervention for primary hyperparathyroidism offers greater bone recovery in patients with sporadic disease than in those with multiple endocrine neoplasia type 1–related hyperparathyroidism. Surgery, 2017, 161, 107-115.	1.9	16
50	De Novo Development Of A Cortisol-Producing Adrenocortical Carcinoma In A Patient With Primary Adrenal Insufficiency. AACE Clinical Case Reports, 2017, 3, e162-e165.	1.1	0
51	Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4871-4877.	3.6	35
52	Medullary Thyroid Carcinoma Associated with Germline <i>RET^{K666N}</i> Mutation. Thyroid, 2016, 26, 1744-1751.	4.5	7
53	Molecular diagnostics and anaplastic thyroid carcinoma: the time has come to harvest the high hanging fruit. International Journal of Endocrine Oncology, 2016, 3, 221-233.	0.4	15
54	Detection and Prognostic Significance of Circulating Tumor Cells in Patients With Metastatic Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4461-4467.	3.6	41

#	Article	IF	CITATIONS
55	Radionuclide Imaging and Treatment of Children with Thyroid Cancer. , 2016, , 475-485.		0
56	Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma. Pituitary, 2016, 19, 415-421.	2.9	16
57	A Young Child with Papillary Thyroid Cancer and Metastatic Pulmonary Disease: Role of Radioactive Iodine Therapy in Children. , 2016, , 229-236.		0
58	Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis. Endocrine, 2016, 51, 351-359.	2.3	27
59	A Child with Papillary Thyroid Cancer and Locally Advanced Disease but No Distant Metastasis. , 2016, , 111-118.		0
60	Follicular Thyroid Cancer: Special Aspects in Children and Adolescents. , 2016, , 801-805.		0
61	Inherited Medullary Thyroid Carcinoma: Indications and Technique of Early ThyroidectomyEarly thyroidectomy. , 2016, , 85-94.		0
62	RET Fusion as a Novel Driver of Medullary Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 788-793.	3.6	65
63	Fatal juvenile xanthogranuloma presenting as a sellar lesion: case report and literature review. Child's Nervous System, 2015, 31, 777-784.	1.1	18
64	Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid, 2015, 25, 567-610.	4.5	1,738
65	Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 2015, 25, 716-759.	4.5	881
66	Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy—A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2192-2203.	3.6	96
67	Functional imaging for pheochromocytoma–paraganglioma: a step closer to understanding its place in clinical practice. Endocrine, 2015, 50, 6-8.	2.3	9
68	Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer–Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. Thyroid, 2015, 25, 1085-1090.	4.5	22
69	BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i> -Mutant Thyroid Cancer. Thyroid, 2015, 25, 71-77.	4.5	189
70	Efficacy and Tolerability of Vemurafenib in Patients with BRAFV600E -Positive Papillary Thyroid Cancer: M.D. Anderson Cancer Center Off Label Experience. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E77-E81.	3.6	109
71	Visual Vignette. Endocrine Practice, 2014, 20, 191.	2.1	0

Pheochromocytoma and multiple endocrine neoplasia syndromes. , 2014, , 533-568.e1.

5

#	Article	IF	CITATIONS
73	Efficacy and Tolerability of Different Starting Doses of Sorafenib in Patients With Differentiated Thyroid Cancer. Oncologist, 2014, 19, 477-482.	3.7	24
74	Feasibility and outcome of re-irradiation in the treatment of multiply recurrent pituitary adenomas. Pituitary, 2014, 17, 539-545.	2.9	24
75	Preoperative multiple endocrine neoplasia type 1 diagnosis improves the surgical outcomes of pediatric patients with primary hyperparathyroidism. Journal of Pediatric Surgery, 2014, 49, 546-550.	1.6	14
76	Adrenal ganglioneuroma: features and outcomes of 27 cases at a referral cancer centre. Clinical Endocrinology, 2014, 80, 342-347.	2.4	51
77	Prevalence by Age and Predictors of Medullary Thyroid Cancer in Patients with Lower Risk Germline RET Proto-Oncogene Mutations. Thyroid, 2014, 24, 1096-1106.	4.5	40
78	Role of Salvage Targeted Therapy in Differentiated Thyroid Cancer Patients Who Failed First-Line Sorafenib. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2086-2094.	3.6	87
79	Thyroid Carcinoma, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1671-1680.	4.9	147
80	Impact and timing of bilateral adrenalectomy for refractory adrenocorticotropic hormoneâ^'dependent Cushing's syndrome. Surgery, 2013, 154, 1174-1184.	1.9	33
81	Endocrine Tumors Associated with Neurofibromatosis Type 1, Peutz-Jeghers Syndrome and Other Familial Neoplasia Syndromes. Frontiers of Hormone Research, 2013, 41, 166-181.	1.0	12
82	Ultrasonography Should Not Guide the Timing of Thyroidectomy in Pediatric Patients Diagnosed with Multiple Endocrine Neoplasia Syndrome 2A through Genetic Screening. Annals of Surgical Oncology, 2013, 20, 53-59.	1.5	38
83	The Noninvestigational Use of Tyrosine Kinase Inhibitors in Thyroid Cancer: Establishing a Standard for Patient Safety and Monitoring. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 31-42.	3.6	80
84	Thyroid Neoplasia. , 2013, , 319-336.		0
85	The Characterization of Pheochromocytoma and Its Impact on Overall Survival in Multiple Endocrine Neoplasia Type 2. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1813-E1819.	3.6	82
86	Bone Metastases and Skeletal-Related Events in Patients With Malignant Pheochromocytoma and Sympathetic Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1492-1497.	3.6	94
87	Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. European Journal of Endocrinology, 2013, 169, 891-899.	3.7	235
88	A Retrospective Cohort Analysis of the Efficacy of Adjuvant Radiotherapy after Primary Surgical Resection in Patients with Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 192-197.	3.6	86
89	Treatment with Sunitinib for Patients with Progressive Metastatic Pheochromocytomas and Sympathetic Paragangliomas. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4040-4050.	3.6	185
90	Phospho-histone H3 (pHH3) immuno-reactivity as a prognostic marker in non-functioning pituitary adenomas. Pituitary, 2012, 15, 556-561.	2.9	6

#	Article	IF	CITATIONS
91	Long-term follow-up data may help manage patient and parent expectations for pediatric patients undergoing thyroidectomy. Surgery, 2012, 152, 1165-1171.	1.9	27
92	Medical Management Of Postsurgical Hypoparathyroidism. Endocrine Practice, 2011, 17, 18-25.	2.1	99
93	Management of medullary thyroid carcinoma and MEN2 syndromes in childhood. Nature Reviews Endocrinology, 2011, 7, 596-607.	9.6	105
94	Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion. Cancer, 2011, 117, 4381-4389.	4.1	135
95	An individualized approach to the child with thyroid cancer. Expert Review of Endocrinology and Metabolism, 2011, 6, 85-92.	2.4	1
96	Random Postoperative Day-3 Cortisol Concentration as a Predictor of Hypothalamic-Pituitary-Adrenal Axis Integrity after Transsphenoidal Surgery. Endocrine Practice, 2011, 17, 717-726.	2.1	11
97	Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Medullary and Differentiated Thyroid Malignancies. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 997-1005.	3.6	100
98	Multiple Endocrine Neoplasia Type 2B with a <i>RET</i> Proto-Oncogene A883F Mutation Displays a More Indolent Form of Medullary Thyroid Carcinoma Compared with a <i>RET</i> M918T Mutation. Thyroid, 2011, 21, 189-192.	4.5	66
99	Acute-Onset Ectopic Adrenocorticotropic Hormone Syndrome Secondary to Metastatic Endometrioid Carcinoma of the Ovaries As a Fatal Complication. Journal of Clinical Oncology, 2011, 29, e462-e464.	1.6	7
100	Long-Term Outcome of Comprehensive Central Compartment Dissection in Patients with Recurrent/Persistent Papillary Thyroid Carcinoma. Thyroid, 2011, 21, 1309-1316.	4.5	81
101	Gonadotropin-Dependent Precocious Puberty: Neoplastic Causes and Endocrine Considerations. International Journal of Pediatric Endocrinology (Springer), 2011, 2011, 184502.	1.6	47
102	Thyroid Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 1228-1274.	4.9	194
103	Initial Management and Follow-up of Differentiated Thyroid Cancer in Children. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 1289-1300.	4.9	45
104	Medullary Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 512-530.	4.9	70
105	Do the recent American Thyroid Association (ATA) Guidelines accurately guide the timing of prophylactic thyroidectomy in MEN2A?. Surgery, 2010, 148, 1302-1310.	1.9	28
106	Multiple endocrine syndrome type 2B in early childhood. Cancer, 2010, 116, 2284-2284.	4.1	14
107	A Current Review of the Etiology, Diagnosis, and Treatment of Pediatric Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2023-2037.	3.6	209
108	Spontaneous involution of Rathke cleft cysts: is it rare or just underreported?. Journal of Neurosurgery, 2010, 112, 1327-1332.	1.6	46

#	Article	IF	CITATIONS
109	Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson Experience. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2588-2595.	3.6	183
110	The Successful Use of Sorafenib to Treat Pediatric Papillary Thyroid Carcinoma. Thyroid, 2009, 19, 407-412.	4.5	54
111	Use of the Tyrosine Kinase Inhibitor Sunitinib in a Patient with von Hippel-Lindau Disease: Targeting Angiogenic Factors in Pheochromocytoma and Other von Hippel-Lindau Disease-Related Tumors. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 386-391.	3.6	120
112	Thyroid Cancer in Young Adults. Seminars in Oncology, 2009, 36, 258-274.	2.2	22
113	Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma. Head and Neck, 2009, 31, 1152-1163.	2.0	78
114	Surgical Management of Nonmultiple Endocrine Neoplasia Endocrinopathies: State-of-the-Art Review. Surgical Clinics of North America, 2009, 89, 1069-1089.	1.5	16
115	A Perspective from Pediatric Endocrinology on the Hereditary Medullary Thyroid Carcinoma Syndromes. Thyroid, 2009, 19, 543-546.	4.5	10
116	Failure to Recognize Multiple Endocrine Neoplasia 2B: More Common Than We Think?. Annals of Surgical Oncology, 2008, 15, 293-301.	1.5	85
117	In Brief. Current Problems in Surgery, 2008, 45, 149-151.	1.1	7
118	Recent Advances in Thyroid Cancer. Current Problems in Surgery, 2008, 45, 156-250.	1.1	61
119	Multisystem Crisis in a Patient with Presumptive Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2008, 6, 128-130.	1.9	1
120	Premonitory symptoms preceding metastatic medullary thyroid cancer in multiple endocrine neoplasia type 2B: An exploratory analysis. Surgery, 2008, 144, 1052-1053.	1.9	0
121	A Novel Von Hippel–Lindau Point Mutation Presents as Apparently Sporadic Pheochromocytoma. Cancer Investigation, 2008, 26, 642-646.	1.3	2
122	Autosomal Dominant Osteopetrosis: Clinical Severity and Natural History of 94 Subjects with a Chloride Channel 7 Gene Mutation. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 771-778.	3.6	129
123	Transient Hypophysitis after Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA4) Blockade. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1201-1202.	3.6	15
124	Metastatic Melanoma to the Pituitary Gland. Canadian Journal of Neurological Sciences, 2007, 34, 322-327.	0.5	33
125	Primary adrenal natural killer/T-cell nasal type lymphoma: First case report in adults. American Journal of Hematology, 2007, 82, 299-303.	4.1	17
126	Management of Pancreatic Endocrine Tumors in Multiple Endocrine Neoplasia Type 1. World Journal of Surgery, 2006, 30, 643-653.	1.6	151

#	Article	IF	CITATIONS
127	Adrenal Ganglioneuromas in Children with Multiple Endocrine Neoplasia Type 2: A Report of Two Cases. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4383-4387.	3.6	51
128	Adrenal Pseudocyst. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3067-3068.	3.6	7
129	Analysis of variation in expression of autosomal dominant osteopetrosis type 2: Searching for modifier genes. Bone, 2005, 37, 655-661.	2.9	35
130	Severe Infantile Hypercalcemia Associated With Williams Syndrome Successfully Treated With Intravenously Administered Pamidronate. Pediatrics, 2004, 114, 1091-1095.	2.1	50
131	Osteoclast-Derived Serum Tartrate-Resistant Acid Phosphatase 5b in Albers-Schol^nberg Disease (Type II) Tj ETQq	1 1 0.7843 3.2	814 rgBT /O
132	Surgical management of hereditary pheochromocytoma1 1No competing interests declared Journal of the American College of Surgeons, 2004, 198, 525-534.	0.5	120
133	Parathyroid carcinoma: A 22-year experience. Head and Neck, 2004, 26, 716-726.	2.0	233
134	Chloride Channel 7 (ClCN7) Gene Mutations and Autosomal Dominant Osteopetrosis, Type II. Journal of Bone and Mineral Research, 2003, 18, 1513-1518.	2.8	88
135	Expansile intraosseus lesion of the mandible. Journal of Oral and Maxillofacial Surgery, 2003, 61, 1318-1323.	1.2	14
136	Acute Painful Neuropathy (Insulin Neuritis) in a Boy Following Rapid Glycemic Control for Type 1 Diabetes Mellitus. Journal of Child Neurology, 2003, 18, 365-367.	1.4	27
137	Case 29-2001: Oncogenic Hypophosphatemic Osteomalacia. New England Journal of Medicine, 2002, 346, 381-382.	27.0	6
138	Measurement of Tartrate-Resistant Acid Phosphatase and the Brain Isoenzyme of Creatine Kinase Accurately Diagnoses Type II Autosomal Dominant Osteopetrosis but Does Not Identify Gene Carriers. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2212-2217.	3.6	36